Daytrana gains indication for attention deficit hyperactivity disorder (ADHD) in adolescents - MPR
Links shared publicly online about this topic.
- 1,039total visits
Daytrana gains indication for attention deficit hyperactivity disorder (ADHD) in adolescents - MPR
empr.com —
View full resource at empr.com
Tags: ADHD, ADHD Medication, Disease and Condition, FDA, Concerta, Metadate CD, Metadate ER, Methylin
Most Recently Shared on July 7, 2010 at 3:13 pm By:
MPR News: Daytrana gains indication for attention deficit hyperactivity disorder (ADHD) in adolescents: The FDA ha... http://bit.ly/boPPmm
Intuniv gains indication as adjunctive therapy in ADHD - ONA
oncologynurseadvisor.com — “Shire announced that the FDA has approved Intuniv (guanfacine extended-release tablets) for use as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6--17 years as part of a total treatment program.” View full resource at oncologynurseadvisor.com
Most Recently Shared on February 28, 2011 at 3:40 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Intuniv gains indication as adjunctive therapy in ADHD http://goo.gl/fb/srbUs
Vyvanse gains indication for ADHD in adolescents - ONA
oncologynurseadvisor.com — “The FDA has approved Vyvanse (lidexamfetamine dimesylate capsules, from Shire) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents 13--17 years of age.” View full resource at oncologynurseadvisor.com
Most Recently Shared on November 15, 2010 at 3:38 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Vyvanse gains indication for ADHD in adolescents http://goo.gl/fb/EQzPw
Shire receives FDA approval of Daytrana for ADHD in adolescents
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include ” View full resource at news-medical.net
Most Recently Shared on July 7, 2010 at 5:40 am By:
Shire receives FDA approval of Daytrana for ADHD in adolescents: Shire plc, the global specialty biopharmaceutical... http://bit.ly/atTr4s
Advertisement
